Mar 12, 2024 8:00am EDT Veru Announces the Appointment of Louis Aronne MD as Chief Medical Advisor for its Enobosarm Program for High Quality Weight Loss
Feb 27, 2024 7:15pm EST Veru Announces Notification from Nasdaq Related to Delayed Quarterly Report on Form 10-Q
Feb 20, 2024 8:30am EST Veru Announces New Scientific Advisory Board for its Enobosarm Program for High Quality Weight Loss
Feb 06, 2024 8:30am EST Veru Announces FDA Clearance of IND Application to Initiate Phase 2b Clinical Trial with Enobosarm to Treat Muscle Loss Associated with Weight Loss Drugs
Jan 31, 2024 8:30am EST Veru to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
Jan 25, 2024 8:30am EST Veru to Report Fiscal 2024 First Quarter Financial Results on February 8, 2024
Jan 08, 2024 8:30am EST Veru Submits IND Application to FDA for the Development of Enobosarm to Prevent Muscle Loss While Augmenting Fat Loss in Combination with GLP-1 Drugs for Weight Loss
